[1] Liaw YF,Chu CM.Hepatitis B virus infection. Lancet,2009,373(9663):582-591. [2] Cheng S,Zhang B,Du JY,et al.Hepatitis B surface antigen promotes the invasion of hepatitis B virus-related hepatocellular carcinoma cells by upregulation of toll-like receptor 2. Viral Immunol,2017,30(3):232-239. [3] Hsu HY,Chang MH,Ni YH,et al.Chronologic changes of serum hepatitis B virus DNA,genotypes,surface antigen mutants and reverse transcriptase mutants during 25-year nationwide immunization in Taiwan. J Viral Hepat,2017,24(8):645-653. [4] Shimizu T,Tanaka T,Uno S,et al.Detection of antibodies against hepatitis B virus surface antigen and hepatitis C virus core antigen in plasma with a waveguide-mode sensor. J Biosci Bioeng,2017,123(6):760-764. [5] Brunetto MR,Oliveri F,Colombatto P,et al.Hepatitis B surface antigen serum levels help to distinguish active from inactive hepatitis B virus genotype D carriers. Gastroenterology,2010,139(2):483-490. [6] Sonneveld MJ,Zoutendijk R,Janssen HL.Hepatitis B surface antigen monitoring and management of chronic hepatitis B. J Viral Hepat,2011,18(7):449-457. [7] Tan Z,Li M,Kuang X,et al.Clinical implications of hepatitis B surface antigen quantitation in the natural history of chronic hepatitis B virus infection. J Viral Hepat,2014,59(4):228-235. [8] 沈小英,冯雪君. 低水平乙型肝炎表面抗原测定与HBV-DNA关系的研究. 中华医院感染学杂志,2012,22(24):5463-5465. [9] Kleiner D.Histopathology,grading and staging of nonalcoholic fatty liver disease. Minerva Gastroenterol Dietol,2017,64(1):28-38. [10] Martinotpeignoux M,Lapalus M,Asselah T,et al.The role of HBsAg quantification for monitoring natural history and treatment outcome. Liver Int,2013,33(1):125-132. [11] Thibault V,Servant-Delmas A,Ly TD,et al.Performance of HBsAg quantification assays for detection of hepatitis B virus genotypes and diagnostic escape-variants in clinical samples. J Clin Virol,2017,89:14-21. [12] 刘立,刘春云,王霖,等. 低水平HBsAg患者肝脏组织病理学变化及其相关因素分析. 中华肝脏病杂志,2017,25(7):1-6. [13] Mukherjee RM,Reddy PB,Arava J,et al.Relationship between serum HBsAg level,HBV DNA level,and peripheral immune cells in patients with chronic hepatitis B virus infection. Hepat Med,2010,2:157-162. [14] Peng CY,Lai HC,Li YF,et al.Early serum HBsAg level as a strong predictor of sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B. Aliment Pharmacol Ther,2012,35(4):458-468. [15] Takkenberg RB,Jansen L,De NA,et al.Baseline hepatitis B surface antigen(HBsAg) as predictor of sustained HBsAg loss in chronic hepatitis B patients treated with pegylated interferon-α2a and adefovir. Antivir Ther,2013,18(7):895-904. [16] Zhao J,Zhang Z,Luan Y,et al.Pathological functions of interleukin-22 in chronic liver inflammation and fibrosis with HBV infection by promoting Th17 cell recruitment. Hepatology,2014,59(4):1331-1342. [17] Liu C,Wu W,Shang H,et al.Prediction value of serum HBV large surface protein in different phases of HBV infection and virological response of chronic hepatitis B patients. Clin Chim Acta,2018,481:12-19. [18] Morenootero R,Traperomarugan M,Mendoza J.Liver fibrosis assessment by transient elastography in hepatitis C patients with normal alanine aminotransferase. Gut,2006,55(7):1055-1056.[19] Minervino AH,Barrêto Júnior RA,Queiroz GF,et al. Predictive values of aspartate aminotransferase and gamma-glutamyl transferase for the hepatic accumulation of copper in cattle and buffalo. J Vet Diagn Invest,2008,20(6):791-795. [20] Carobene A,Braga F,Roraas T,et al.A systematic review of data on biological variation for alanine aminotransferase,aspartate aminotransferase and γ-glutamyl transferase. Clin Chem Lab Med,2013,51(10):1997-2007. |